Ferro A, Gilbert R, Krum H
Department of Clinical Pharmacology, Cardiovascular Division, GKT School of Medicine, King's College London, London, UK.
Int J Clin Pract. 2006 May;60(5):577-81. doi: 10.1111/j.1368-5031.2006.00920.x.
Despite improvements in its detection and treatment, hypertension remains a significant public health problem worldwide. In recent years, many international hypertension societies and organisations have set increasingly rigorous blood pressure (BP) targets, with the aim of reducing cardiovascular complications, and this has in turn necessitated the use of more antihypertensive medications to reach these targets in individual patients. There is therefore an ongoing need to develop antihypertensive drugs with new mechanisms of action. Renin inhibitors represent a novel class of compounds which offer considerable promise as BP-lowering agents. Here, we review the rationale for renin inhibition as a therapeutic target and examine the preclinical and clinical evidence for the antihypertensive effectiveness of the renin inhibitors.
尽管在高血压的检测和治疗方面有所改善,但它在全球范围内仍是一个重大的公共卫生问题。近年来,许多国际高血压学会和组织设定了越来越严格的血压目标,旨在减少心血管并发症,这反过来又需要使用更多的抗高血压药物来使个体患者达到这些目标。因此,持续需要开发具有新作用机制的抗高血压药物。肾素抑制剂是一类新型化合物,作为降压药具有很大的前景。在此,我们综述将肾素抑制作为治疗靶点的理论依据,并考察肾素抑制剂降压有效性的临床前和临床证据。